Raymond James on Legend Biotech Corp. (LEGN): 'Arcellx Takeout Indicates Legend is Hugely Undervalued'

February 23, 2026 9:31 AM EST Send to a Friend
Raymond James analyst Sean McCutcheon reiterated an Outperform rating and $86.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login